The neurochemical effects of anxiolytic drugs are dependent on rearing conditions in Fawn-Hooded rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 3, 2003, Pages 451-458

  Lodge, Daniel J ^a   Lawrence, Andrew J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Anxiety; CCK; Ci 988; Diazepam; Dopamine

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALCOHOL; ANXIOLYTIC AGENT; BACITRACIN; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; DIAZEPAM; DOPAMINE 2 RECEPTOR; ENZYME INHIBITOR; MESSENGER RNA; PREPROCHOLECYSTOKININ; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; GENE EXPRESSION REGULATION; MALE; NEUROCHEMISTRY; NONHUMAN; RAT; RAT STRAIN; REARING; RECEPTOR BINDING; RECEPTOR DENSITY;

EID: 0037403215     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00032-0     Document Type: Article

References (58)

1. Argyropoulos S.V., Sandford J.J., Nutt D.J. The psychobiology of anxiolytic drug: Part 2. Pharmacological treatments of anxiety. Pharmacol. Ther. 88:2000;213-227.
2. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann. N.Y. Acad Sci. 713:1994;273-282.
3. Burazin T.C., Gundlach A.L. Rapid but transient increases in cholecystokinin mRNA levels in cerebral cortex following amygdaloid-kindled seizures in the rat. Neurosci. Lett. 209:1996;65-68.
4. 28,31]CCK-(25-33): a convenient new aminopeptidase resistant cholecystokinin analogue for radioligand binding and autoradiography. Eur. J. Pharmacol. 191:1990;107-110.
5. Charney D.S., Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10:1996;419-446.
6. Conzelmann U., Meyer D.K., Sperk G. Stimulation of receptors of γ-aminobutyric acid modulates the release of cholecystokinin-like immunoreactivity from slices of rat neostriatum. Br. J. Pharmacol. 89:1986;845-852.
7. Crawley J.N. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12:1991;232-236.
8. Del Bel E.A., Guimaraes F.S. Social isolation increases cholecystokinin mRNA in the central nervous system of rats. Neuroreport. 8:1997;3597-3600.
9. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994;133-141.
10. Fendt M., Fanselow M.S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci. Biobehav. Rev. 23:1999;743-760.
11. Fernandez-Guasti A. Diazepam, but not buspirone, induces similar anxiolytic-like actions in lactating and ovariectomized Wistar rats. Pharmacol. Biochem. Behav. 70:2001;85-93.
12. Ferraro L., O'Connor W.T., Glennon J., Tomasini M.C., Bebe B.W., Tanganelli S., Antonelli T. Evidence for a nucleus accumbens CCK2 receptor regulation of rat ventral pallidal GABA levels: a dual probe microdialysis study. Life Sci. 68:2000;483-496.
13. File S.E. Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action. Brain Res. 888:2001;311-313.
14. Fossa A.A., DePasquale M.J., Morrone J., Zorn S.H., Bryce D., Lowe J.A., McLean S. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog. J. Pharmacol. Exp. Ther. 281:1997;180-187.
15. Gillis R.A., Quest J.A., Pagani F.D., Souza J.D., Da Silva A.M., Jensen R.T., Garvey T.Q., Hamosh P. Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat. J. Pharmacol. Exp. Ther. 224:1983;408-414.
16. Hall F.S., Wilkinson L.S., Humby T., Inglis W., Kendall D.A., Marsden C.A., Robbins T.W. Isolation-rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol. Biochem. Behav. 59:1998;859-872.
17. Harro J., Kiivet R.A., Lang A., Vasar E. Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav. Brain Res. 39:1990;63-71.
18. Harro J., Lang A., Vasar E. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur. J. Pharmacol. 180:1990;77-83.
19. Hutchinson M.A., Smith P.F., Darlington C.L. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog. Neurobiol. 49:1996;73-97.
20. Koch M. The neurobiology of startle. Prog. Neurobiol. 59:1999;107-128.
21. LaBuda C.J. The anxiolytic effect of acute ethanol or diazepam exposure is unaltered in μ-opioid receptor knockout mice. Brain Res. Bull. 55:2001;755-760.
22. Ladurelle N., Keller G., Roques B.P., Dauge V. Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 628:1993;254-262.
23. Lança A.J., De Cabo C., Arifuzzaman A.I., Vaccarino F.J. Cholecystokinergic innervation of nucleus accumbens subregions. Peptides. 19:1998;859-868.
24. Lang P.J., Bradley M.M., Cuthbert B.N. Emotion, motivation, and anxiety: brain mechanisms and psychophysiology. Biol. Psychiatry. 44:1998;1248-1263.
25. 2 receptors on rat vagal afferent neurones. Br. J. Pharmacol. 114:1995;1329-1334.
26. Lawrence A.J., Krstew E., Jarrott B. Actions of nitric oxide and expression of the mRNA encoding nitric oxide synthase in rat vagal afferent neurons. Eur. J. Pharmacol. 315:1996;127-133.
27. 2 receptors in rat forebrain sections. Eur. J. Neurosci. 7:1995;962-971.
28. Lodge D.J., Lawrence A.J. Comparative analysis of the central CCK system in Fawn Hooded and Wistar Kyoto rats: extended localisation of CCK-A receptors throughout the rat brain using a novel radioligand. Regul. Pept. 99:2001;191-201.
29. Lodge D.J., Lawrence A.J. The effect of isolation rearing on volitional ethanol consumption and central CCK/dopamine systems in Fawn-Hooded rats. Behav. Brain Res. 2003;. (in press).
30. 1 receptor antagonist, antalarmin reduces volitional ethanol consumption in isolation-reared Fawn-Hooded rats. Neuroscience. 2003;. (in press).
31. Lodge D.J., Short J.L., Mercer L.D., Beart P.M., Lawrence A.J. CCK/dopamine interactions in Fawn-Hooded and Wistar-Kyoto rat brain. Peptides. 21:2000;379-386.
32. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
33. Matto V., Harro J., Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology. 36:1997;389-396.
34. McGregor I.S., Schrama L., Ambermoon P., Dielenberg R.A. Not all 'predator odours' are equal: cat odour but not 2,4,5 trimethylthiazoline (TMT; fox odour) elicits specific defensive behaviours in rats. Behav. Brain Res. 129:2002;1-16.
35. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 23:1999;591-613.
36. Nakamura K., Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur. J. Pharmacol. 420:2001;33-43.
37. National Health and Medical Research Council (NHMRC) (Australia), 1997. Australian Code of Practice for the Care and Use of Animals for Scientific Purposes ( http://www.nhmrc.gov.au/research/awc/code.htm ).
38. National Institute of Mental Health (NIMH) Anxiety Disorders. 2000; http://www.nimh.nih.gov/anxiety/anxiety.pdf.
39. Nutt D.J. Benzodiazepine dependence: new insights from basic research. Hindmarch I., Beaumont G., Brandon S., Leonard B.E. Benzodiazepines: Current Concepts. 1990;19-41 Wiley, Chichester.
40. Pavlasevic S., Bednar I., Qureshi G.A., Sodersten P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport. 5:1993;225-228.
41. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. 1986;Academic Press Australia, Sydney.
42. Pei G., Ebendal T. Specific lesions in the extrapyramidal system of the rat brain induced by 3-nitropropionic acid (3-NPA). Exp. Neurol. 132:1995;105-115.
43. Rehfeld J.F. CCK and anxiety. Dourish C.T., Cooper S.J., Iversen S.D., Iversen L.L. Multiple Cholecystokinin Receptors in the CNS. 1992;117-120 Oxford Univ. Press, London.
44. Rex A., Barth T., Voigt J.P., Domeney A.M., Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172:1994;139-142.
45. 4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology. 33:1994;559-565.
46. Rezvani A.H., Parsian A., Overstreet D.H. The Fawn-Hooded (FH/Wjd) rat: a genetic animal model of comorbid depression and alcoholism. Psychiatr. Genet. 12:2002;1-16.
47. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol. Biochem. Behav. 52:1995;805-813.
48. Sandford J.J., Argyropoulos S.V., Nutt D.J. The psychobiology of anxiolytic drugs: Part 1. Basic neurobiology. Pharmacol. Ther. 88:2000;197-212.
49. Seroogy K.B., Fallon J.H. Forebrain projections from cholecystokinin-like-immunoreactive neurons in the rat midbrain. J. Comp. Neurol. 279:1989;415-435.
50. Seroogy K.B., Dangaran K., Lim S., Haycock J.W., Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J. Comp. Neurol. 279:1989;397-414.
51. Singh L., Field M.J., Hughes J., Menzies R., Oles R.J., Vass C.A., Woodruff G.N. The behavioural properties of CI-988, a selective cholecystokinin-B receptor antagonist. Br. J. Pharmacol. 104:1991;239-245.
52. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin-B receptor in anxiety. Proc. Natl. Acad. Sci. USA. 88:1991;1130-1133.
53. 2 receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 902:2001;135-142.
54. Taukulis H.K., Goggin C.E. Diazepam-stress interactions in the rat: effects on autoanalgesia and a plus-maze model of anxiety. Behav. Neural Biol. 53:1990;205-216.
55. Vaccarino F.J., Vaccarino A.L. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward. Neurosci. Lett. 97:1989;151-156.
56. Woods S.C., Seeley R.J., Porte D. Jr., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science. 280:1998;1378-1383.
57. Wright I.K., Upton N., Marsden C.A. Resocialisation of isolation-reared rats does not alter their anxiogenic profile on the elevated X-maze model of anxiety. Physiol. Behav. 50:1991;1129-1132.
58. Yaksh T.L., Furui T., Kanawati I.S., Go V.L. Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems. Brain Res. 406:1987;207-214.